Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2019 Jul 8

PMID 31280474

Citations 8

Authors

Hu Peng

Yue Deng

Longhao Wang

Yin Cheng

Yaping Xu

Jianchun Liao

Hao Wu

Affiliations

Soon will be listed here.

Abstract

Pituitary adenomas are the most common intrasellar tumors. Patients should be identified at an early stage so that effective treatment can be implemented. The study aims at detecting the potential biomarkers with diagnostic value of pituitary adenomas. Using a total of seven gene expression profiles (GEPs) of the datasets from the Gene Expression Omnibus (GEO) database, we first screened 1980 significant differentially expressed genes (DEGs). Then, we employed the prediction analysis for microarray (PAM) algorithm to identify 340 significant DEGs able to differ pituitary tumor from normal samples, which include 208 upregulated DEGs and 132 downregulated DEGs. DAVID database was used to carry out the enrichment analysis on Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathways. We found that upregulated candidates were enriched in protein folding and metabolic pathways. Downregulated DEGs saw a significant enrichment in insulin receptor signaling pathway and hedgehog signaling pathway. Based on the protein-protein interaction (PPI) network as well as module analysis, we determined ten hub genes including PHLPP, ENO2, ACTR1A, EHHADH, EHMT2, FOXO1, DLD, CCT2, CSNK1D, and CETN2 that could be potential biomarkers with diagnostic value in pituitary adenomas. In conclusion, the study contributes to reliable and potential molecular biomarkers with diagnostic value. Moreover, these potential biomarkers may be used for prognosis and new therapeutic targets for the pituitary adenomas.

Citing Articles

VHL-dependence of EHHADH Expression in a Human Renal Cell Carcinoma Cell Line.

Pilz J, Klein M, Neumann-Haefelin E, Ganner A J Kidney Cancer VHL. 2024; 11(1):12-18.

PMID: 38304003 PMC: 10834178. DOI: 10.15586/jkcvhl.v11i1.322.

Early diagnostic and prognostic biomarkers for gastric cancer: systems-level molecular basis of subsequent alterations in gastric mucosa from chronic atrophic gastritis to gastric cancer.

Selvan T, Gollapalli P, Kumar S, Ghate S J Genet Eng Biotechnol. 2023; 21(1):86.

PMID: 37594635 PMC: 10439097. DOI: 10.1186/s43141-023-00539-0.

The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells.

Capoferri D, Chiodelli P, Corli M, Belleri M, Scalvini E, Mignani L Int J Mol Sci. 2023; 24(13).

PMID: 37445731 PMC: 10342161. DOI: 10.3390/ijms241310555.

[EHHADH is a key gene in fatty acid metabolism pathways in hepatocellular carcinoma: a transcriptomic analysis].

Xie S, Li M, Jiang F, Yi Q, Yang W Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(5):680-693.

PMID: 37313808 PMC: 10267234. DOI: 10.12122/j.issn.1673-4254.2023.05.02.

High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.

Qiu P, Deng X, Li L Clin Transl Oncol. 2022; 25(5):1340-1352.

PMID: 36527574 DOI: 10.1007/s12094-022-03031-2.

References

Michaelis K, Knox A, Xu M, Kiseljak-Vassiliades K, Edwards M, Geraci M . Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology. 2011; 152(10):3603-13. PMC: 4714647. DOI: 10.1210/en.2011-0109. View

Wang W, Xu Z, Fu L, Liu W, Li X . Pathogenesis analysis of pituitary adenoma based on gene expression profiling. Oncol Lett. 2014; 8(6):2423-2430. PMC: 4214395. DOI: 10.3892/ol.2014.2613. View

Liu Z, Wu C, Miao H, Wu H . RegNetwork: an integrated database of transcriptional and post-transcriptional regulatory networks in human and mouse. Database (Oxford). 2015; 2015. PMC: 4589691. DOI: 10.1093/database/bav095. View

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

Ezzat S, Asa S, Couldwell W, Barr C, Dodge W, Vance M . The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101(3):613-9. DOI: 10.1002/cncr.20412. View

Molitch M . Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017; 317(5):516-524. DOI: 10.1001/jama.2016.19699. View

Gueorguiev M, Grossman A . Pituitary tumors in 2010: a new therapeutic era for pituitary tumors. Nat Rev Endocrinol. 2011; 7(2):71-3. DOI: 10.1038/nrendo.2010.233. View

Liu C, Wang H, Wang W, Wang L, Liu W, Wang J . ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia. Cell Physiol Biochem. 2018; 46(4):1525-1535. DOI: 10.1159/000489196. View

Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A . Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006; 312(5777):1228-30. DOI: 10.1126/science.1126100. View

10.

Zhao P, Hu W, Wang H, Yu S, Li C, Bai J . Identification of differentially expressed genes in pituitary adenomas by integrating analysis of microarray data. Int J Endocrinol. 2015; 2015:164087. PMC: 4302352. DOI: 10.1155/2015/164087. View

11.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

12.

Tong Y, Zheng Y, Zhou J, Oyesiku N, Koeffler H, Melmed S . Genomic characterization of human and rat prolactinomas. Endocrinology. 2012; 153(8):3679-91. PMC: 3404356. DOI: 10.1210/en.2012-1056. View

13.

Zhou W, Ma C, Xing Y, Yan Z . Identification of candidate target genes of pituitary adenomas based on the DNA microarray. Mol Med Rep. 2016; 13(3):2182-6. DOI: 10.3892/mmr.2016.4785. View

14.

Nijaguna M, Patil V, Hegde A, Chandramouli B, Arivazhagan A, Santosh V . An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals. PLoS One. 2015; 10(9):e0137524. PMC: 4577083. DOI: 10.1371/journal.pone.0137524. View

15.

Xiong X, Wen Y, Mitov M, C Oaks M, Miyamoto S, Gao T . PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells. Cell Death Discov. 2017; 3:16103. PMC: 5253420. DOI: 10.1038/cddiscovery.2016.103. View

16.

Morris D, Musat M, Czirjak S, Hanzely Z, Lillington D, Korbonits M . Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol. 2005; 153(1):143-51. DOI: 10.1530/eje.1.01937. View

17.

Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002; 99(10):6567-72. PMC: 124443. DOI: 10.1073/pnas.082099299. View

18.

Fan S, Liang Z, Gao Z, Pan Z, Han S, Liu X . Identification of the key genes and pathways in prostate cancer. Oncol Lett. 2018; 16(5):6663-6669. PMC: 6202544. DOI: 10.3892/ol.2018.9491. View

19.

Strickland A, Rivera G, Lucas E, John G, Cuevas I, Castrillon D . PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia. Int J Gynecol Pathol. 2018; 38(6):503-513. DOI: 10.1097/PGP.0000000000000549. View

20.

Mathioudakis N, Salvatori R . Pituitary tumors. Curr Treat Options Neurol. 2009; 11(4):287-96. DOI: 10.1007/s11940-009-0032-6. View